Jazz Reaches New 52-Week High (JAZZ)

NEW YORK (TheStreet) -- Jazz Pharmaceuticals (Nasdaq:JAZZ) hit a new 52-week high Friday as it is currently trading at $51.55, above its previous 52-week high of $51.36 with 651,864 shares traded as of 11:35 a.m. ET. Average volume has been 766,900 shares over the past 30 days.

Jazz has a market cap of $1.94 billion and is part of the health care sector and drugs industry. Shares are up 25.7% year to date as of the close of trading on Thursday.

Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products to meet unmet medical needs. The company has a P/E ratio of 19.1, above the average drugs industry P/E ratio of 18.5 and above the S&P 500 P/E ratio of 17.7.

• Sign up for TheStreet's FREE Dividend and Income Investor Newsletter

TheStreet Ratings rates Jazz as a buy. The company's strengths can be seen in multiple areas, such as its notable return on equity, robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and impressive record of earnings per share growth. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. You can view the full Jazz Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

For more information on Jazz Pharmaceuticals PLC click any of the following:

• Jazz Pharmaceuticals PLC Stock Price

• Jazz Pharmaceuticals PLC Analyst Ratings

• Jazz Pharmaceuticals PLC Key Stats & Profile

• Jazz Pharmaceuticals PLC Earnings

• Jazz Pharmaceuticals PLC Ratio Comparison

• Jazz Pharmaceuticals PLC Growth Rates

• Jazz Pharmaceuticals PLC Balance Sheet

• Jazz Pharmaceuticals PLC Cash Flow

• Jazz Pharmaceuticals PLC Income Statement